Viatris Reports Quality Defect in Arixtra Pre-Filled Syringes
Viatris has identified a quality defect in Arixtra pre-filled syringes, with reports of brown discolouration and blockage due to needle oxidation.
Asset / Drug
Drug and asset intelligence for Viatris with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.